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The bone marrow (BM) has been identified as a
possible organ for T cell priming, yet the fundamen-
tal mechanisms of a polyclonal immune response
in the BM remain unknown. We found that after
intradermal injection of modified vaccinia Ankara
virus, unexpected sources of newly primed poly-
clonal virus-specific CD8+, but not CD4+, T cells
were localized in the BM and the draining lymph
nodes (dLNs) prior to blood circulation. We identified
neutrophils as the virus-carrier cells from the dermis
to the BM. In both neutrophil-depleted and Ccr1/
mice, virus-specific BM CD8+ responses were lost.
Myeloid antigen-presenting cells were required for
BM CD8+ T cell priming. A systems biology analysis
of dLN and BM virus-specific CD8+ T cells revealed
distinct transcriptional and multifunctional profiles
for cells primed in each organ. We provide direct
evidence for how antigen is transported to the BM,
providing a source of virus-specific memory CD8+
T cells.
INTRODUCTION
Despite the bone marrow (BM) being classically recognized as
the major site of hematopoiesis, recent attention has focused
on its role as a secondary immune organ (Di Rosa and Pabst,
2005; Tokoyoda et al., 2010). Adoptive transfer models of
TCR-transgenic (tg) cells demonstrated that the BMenvironment
could support the priming of T cells to blood-borne antigen (Feu-
erer et al., 2003). Tripp et al. (1997) identified the BM as a site
of T cell priming, although only under conditions of disrupted
lymphocyte trafficking. However, the antigen-presenting cellsI(APCs) were not identified and the results were attributed to
disrupted lymphocyte trafficking. Since then, evidence has
accumulated showing the BM as a preferential organ for CD8+
T cell proliferation, in particular memory CD8+ T cells (Becker
et al., 2005; Mazo et al., 2005; Parretta et al., 2005), and more
recently as a site of resting memory CD4+ T cells (Tokoyoda
et al., 2009).
Activation of naive or memory cells in the BM by APCs opens
the fundamental question of the mechanisms of antigen arrival
in this organ. It has been proposed that circulating dendritic
cells (DCs) can migrate to the BM where they stimulated tg
memory T cells (Cavanagh et al., 2005). However, neutrophils
are often the first cells to arrive at the site of injection or infection.
Depending on the organ and the invading agent, neutrophils can
either activate or dampen the subsequent immune response
(Nathan, 2006). We have previously reported the early re-
cruitment of neutrophils to the dermis after modified vaccinia
Ankara (MVA) intradermal (i.d.) injection and their subsequent
transport of MVA to the draining lymph nodes (dLNs) (Abadie
et al., 2009). In addition it has been demonstrated that senescent
neutrophils also migrate to the BM where they were engulfed by
resident macrophages in the hematopoietic cords (Furze and
Rankin, 2008a).
The arrival of neutrophils and other innate cells to the infection
site is coordinated by a complex milieu of chemokines and their
receptors. One such chemokine receptor, CCR1, is expressed
by neutrophils, monocytes, macrophages, NK cells, and acti-
vated T cells and accounts for their capacity to extravasate
and enter peripheral sites during primary immune responses
(Su et al., 1996). In previous infection models, Ccr1-deficient
mice displayed increased susceptibility to A. fumigatus (Blease
et al., 2000) and T. gondii (Khan et al., 2001) infection compared
to wild-type (WT) mice, suggesting a role for CCR1 in MIP1a-
mediated neutrophil recruitment (Gao et al., 1997). Largely re-
garded as innate effector cells, neutrophils are considered
poor APCs, although they have been reported to prime a tg
T cell response (Beauvillain et al., 2007). In contrast, DCs andmmunity 37, 917–929, November 16, 2012 ª2012 Elsevier Inc. 917
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Figure 1. Bone Marrow T Cell Response
after MVA Intradermal Injection
(A and B) Total number of BrdU+ dividing T cells on
days 0, 3, 4, and 5 after i.d. injection of 53 106 pfu
MVA in dLNs, bone marrow, and blood: (A)
CD8+CD3+ and (B) CD4+CD3+.
(C) Fold increase of CD8+ T cells and CD4+ T cells
on day 5 after i.d. injection of 5 3 106 pfu MVA in
dLNs, BM, and blood.
(D andE) Total numberofBrdU+CD8+ (D) andCD4+
(E) T cells on day 4 after i.d. injection of 53 106 pfu
MVA and i.p. treatment of mice (striped box) with
25 mg FTY-720 on days 1, 2, and 3 detected in
dLNs, BM, and blood. (*p < 0.05, **p < 0.01, ***p <
0.001; Mann-Whitney t test; data are compared to
PBScontrolmice and represent themean+SEMof
three independent experiments, n = 9–12.)
See also Figure S1.
Immunity
Bone Marrow CD8+ T Cell Primingmacrophages express major histocompatibility complex (MHC)
and costimulatory molecules and have been shown to prime
T cells in vivo (Desmedt et al., 1998; Segura and Villadangos,
2009).
We explored the fundamental mechanism by which polyclonal
T cell priming occurred after a physiologically relevant intra-
dermal immunization protocol. We report here the capture
of virus by CCR1+ neutrophils in the dermis, and their subse-
quent migration to the BM, where an interaction with resident
myeloid APCs resulted in an alternative source of primed CD8+
T cells. BM-primed CD8+ T cells exhibited a differential effector
and gene expression profile compared to LN-primed CD8+
T cells.918 Immunity 37, 917–929, November 16, 2012 ª2012 Elsevier Inc.RESULTS
MVA Intradermal Immunization
Induces a Virus-Specific CD8+ T
Cell Response in the Bone Marrow
The bone marrow (BM) has been previ-
ously shown to support a TCR-tg T cell
response, but the most definitive evi-
dence for a polyclonal T cell priming in
the BM is an in-depth in vivo analysis
of the absolute number of proliferative
polyclonal T cells by BrdU incorporation.
After i.d. immunization with 5 3 106 pfu
of MVA, we detected an increased abso-
lute number of virus-specific CD8+ (p =
0.0005) and CD4+ (p = 0.0014) T cells
localized in the BM on day 4 after virus
injection (Figures 1A and 1B). This was
a day later than the proliferation of
T cells in the draining lymph nodes
(dLNs) on day 3, but crucially before we
observed proliferating T cells in the blood
on day 5 (Figures 1A and 1B). CD8+ T cells
in the BM and dLN showed a large expan-
sion: up to a 7-fold increase in cycling
cells on day 5 (Figure 1C). In the BM,
30% of the CD8+ T cells were cyclingcompared to 8% of dLN and 12% of blood CD8+ T cells (Fig-
ure S1 available online). For CD4+ T cells only, the dLN showed
a large expansion (6-fold increase) (Figure 1C) with 8% of cells
dividing on day 5 (Figure S1). These results suggest that a source
of CD8+ T cells could initiate their division in the BM rather than
migrating there after priming in the dLN.
To firmly exclude the possibility that dividing BM T cells were
primed in the dLN and migrate to the BM and proliferate, we
treated MVA-injected mice with FTY-720 (days 1–3), which has
been shown to prevent lymphocyte egress from dLN (Chiba
et al., 1999). When examined on day 4, the dLN showed an
increase in the number of dividing CD8+ T cells in FTY-720-
treated mice, because these cells could no longer exit this organ
Immunity
Bone Marrow CD8+ T Cell Priming(Figure1D).DespiteblockingTcellmigration,wesawasignificant
increase (p=0.0027) in thenumber ofBMBrdU+CD8+Tcells (Fig-
ure 1D). In contrast, accumulation of proliferating CD4+ T cells in
the BM was completely lost after FTY-720 treatment (Figure 1E).
As expected, the blood of FTY-720-treated animals contained no
detectable proliferating T cells, and no differences were seen in
numbers of bloodproliferating Tcells betweenPBS- andMVA-in-
jected mice (Figures 1D and 1E), confirming the efficacy of FTY-
720 treatment. In conclusion, MVA i.d. immunization induces
naive CD8+ T cell priming but not CD4+ T cell priming in the BM.
Neutrophils Transport MVA to the BM after Intradermal
Injection, Resulting in a CD8+ T Cell Response
Wepreviously reported the early recruitment of neutrophils to the
dermis after MVA i.d. injection (Abadie et al., 2009). Because
they have also been reported to migrate to the BM where they
were engulfed by resident macrophages (Furze and Rankin,
2008b), we hypothesized that this was how intradermally in-
jected MVA arrived in the BM. In order to test this, the presence
of MVA in Ly6G+Ly6C+ neutrophils of the dLN, BM, and blood
was examined at 1, 2, and 4 hr after i.d. injection of MVA-
EGFP (Figure 2A). As we previously reported (Abadie et al.,
2009), a significant (p < 0.01) presence of MVA-EGFP in dLN
neutrophils was observed at 4 hr after injection (Figure 2A).
However, at 4 hr after injection we also saw a small but sig-
nificant (p < 0.05) presence of MVA-EGFP in BM neutrophils
(Figure 2A). Interestingly, at 1 hr after injection, we observed a
significant (p < 0.05) MVA-EGFP+ neutrophil population in the
blood (Figure 2A), supporting early circulation of these cells.
No other MVA-EGFP+ populations were detected in the BM or
blood at these time points, in contrast to the dLN where macro-
phages and DCs were the main cell types observed to be MVA-
EGFP+ (data not shown) (Abadie et al., 2009).
To confirm that the EGFP signal detected by flow cytometry
correspond to MVA-EGFP taken up by neutrophils, we also ex-
amined BM cells with an ImageStream flow cytometer (Amnis).
This revealed the presence of BM Ly6G+ neutrophils with intra-
cellular MVA-EGFP at 4 hr after i.d. injection (Figure 2B). The
percentage of EGFP+ neutrophil events (0.3%, data not shown)
as measured by this technique corresponded with the flow
cytometry data.
The transport of MVA by neutrophils from the skin to the BM
was studied with different approaches. First, purified neutrophils
were incubated withMVA for 1 hr, followed by extensive washing
and a 4 hr in vitro rest, to ensure internalization of the virus before
i.d. injection. Interestingly, neutrophils incubated with MVA dis-
played an increase in the expression of CXCR4 by flow cytome-
try analysis, which plays an important role in BM homing (Martin
et al., 2003) as shown in Figure 2C. MVA+ neutrophils also
stained positive for Annexin V, indicating induction of apoptosis
(Figure 2D). To examine whether neutrophils required passage
through the dLN before arrival in the blood and subsequent entry
to the BM, we utilized NOD-SCID IL-2 receptor gamma chain
knockout (NSG) mice that lack lymph nodes. Purified MVA-
bearing CFSE-labeled neutrophils were injected intradermally
into NSG and WT mice. At 1 hr after injection, donor neutrophils
were observed in the BM of both NSG and WT mice, suggesting
a direct migration from the dermis to the BM without passage
through the dLN (Figure 2E).ISecond, to observe the in vivo localization of adoptively trans-
ferred neutrophils within the BM, we performed intravital imaging
on skull BM. Purified neutrophils loaded with MVA were labeled
with Hoechst and injected intradermally. Adoptively transferred
neutrophils could be observed with time-lapse 2-photon laser
scanning microscopy in the BM (Figure 2F; Movies S1 and S2).
The adoptively transferred neutrophils were stationary in the
sinusoidal endothelium during the observed time, in contrast
to the highly motile endogenous neutrophils rolling upon the
vascular flow. We conclude that MVA-loaded neutrophils in-
jected in the skin are able to migrate to the BM.
We then explored whether adoptive transfer of MVA-bearing
neutrophils were able to induce CD8+ T cell proliferation in the
BM in vivo. We first examined the proliferative CD8+ T cell
response via BrdU staining. The i.d. injection of MVA-loaded
neutrophils resulted in a proliferative CD8+ T cell response in
the dLN (Figure 2G) and in the BM on day 4 (Figure 2H). These
results strengthen our previous observations on the role of
neutrophils in the proliferation of CD8+ T cells in the BM.
Finally, to confirm the requirement of endogenous neutrophils
for BMCD8+ T cell priming, we examined T cell proliferation after
an in vivo depletion of neutrophils with the mAb 1A8 (Daley et al.,
2008). Crucially, the dLN CD8+ T cell response persisted after
neutrophil depletion (Figure 2I) in contrast to the BM CD8+
T cell response, which was lost (Figure 2J) (p = 0.0238). Thus,
neutrophils are able to take up viral antigen in the dermis and
migrate to the BM, which results in CD8+ T cell priming.
BM-Primed CD8+ T Cell Response Is Lost in
Ccr1-Deficient Mice
We speculated that the neutrophil-dependent MVA CD8+ T cell
response would be impaired in Ccr1/ mice, because this
receptor is important for neutrophil migration (Gao et al., 1997).
To test this, we examined the presence of neutrophils at the
site of immunization in WT and Ccr1/mice. MVA intradermally
injected skin cryosections were analyzed by immunohistochem-
istry for colocalization of neutrophils andMVA-EGFP (Figure 3A).
Results showed the presence of neutrophils after MVA but not
PBS i.d. injection. Both WT and Ccr1/ neutrophils were colo-
calized with fluorescent viral particles at the site of injection (Fig-
ure 3A). To quantify the numbers of neutrophils arriving in the
dermis after MVA injection, cells were prepared from the dermis
of injected ears and examined by flow cytometry for the pres-
ence of Ly6G+Ly6C+ neutrophils 2 hr after MVA-EGFP injection.
We observed an increase of neutrophils in the dermis of mice at
2 hr after injection of MVA compared to PBS in both WT and
Ccr1/ mice (Figure 3B).
In the blood of WT mice, significant numbers of MVA-EGFP+
neutrophils were observed at 2 hr after injection compared to
both PBS- and MVA-injected Ccr1/ mice. In Ccr1/ mice,
no MVA was detected in blood neutrophils (Figure 3C). In the
dLN, MVA-EGFP+ neutrophils were observed at 2 hr in both
WT and Ccr1/ mice (Figure 3D). In contrast, in the BM signifi-
cant numbers of MVA-EGFP+ neutrophils were observed 2 hr
after injection only in WT mice, not in Ccr1/ mice (Figure 6E).
To examine whether CCR1 was required for entry into the
BM,WT andCcr1/ neutrophils were labeled with CFSE and in-
jected intravenously (i.v.) into WT mice. No differences were
observed in the two groups of recipient mice (Figure S2).mmunity 37, 917–929, November 16, 2012 ª2012 Elsevier Inc. 919
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Figure 2. Neutrophils Transport MVA to the
BM Resulting in a CD8+ T Cell Response
(A) The percentage of EGFP+ neutrophils in the
dLN,BM, andbloodat 1, 2, or 4 hr after i.d. injection
of 107 pfuMVA-EGFP or PBS (*p < 0.05, **p < 0.01;
Mann-Whitney t test; data represent the mean +
SEM of one of three repeated experiments, n = 7).
(B) Example of ImageSteam flow cytometry anal-
ysis of BM Ly6G+EGFP+ neutrophils 4 hr after i.d.
injection of 107 pfu MVA-EGFP.
(C) CXCR4 expression levels of purified neutro-
phils (gray line) cultured with MVA for 1 hr (black
line) (isotype control: light gray fill) as measured by
flow cytometry.
(D) Percentage of Annexin V+ cells in purified
neutrophils cultured with MVA or PBS for 1 hr
measured by flow cytometry.
(E) Representative flow cytometry profile of CFSE+
neutrophils in BM of WT and NSG mice 1 hr after
i.d. injection of MVA-loaded CFSE+ neutrophils.
(F) Two-photon image of BM after i.d. injection of
8 3 106 Hoechst-labeled purified neutrophils
cultured with MVA (i.d. injected neutrophils in
blue) and an i.v. injection of PE-Ly6G antibody
(BM neutrophils in red) (scale bar represents
20 mm) (see also Movies S1 and S2).
(G and H) Total number of BrdU+ dividing CD8+
T cells in the dLN (G) and BM (H) on day 4 after i.d.
injection of 8 3 106 neutrophils cultured with or
without MVA, and i.v. depletion of CD11b+F4/80+
cells with clodronate liposomes (Clod.) (*p < 0.05,
**p < 0.01, ***p < 0.001; Mann-Whitney t test;
graphs represent the mean + SEM of three inde-
pendent experiments, n = 10–12).
(I and J) Total number of BrdU+CD8+ T cells in the
dLN (I) and BM (J) after an i.p. injection of 0.5 mg
1A8 (neutrophils depleting mAb) 24 hr prior to, and
every subsequent 48 hr after, MVA i.d. injection
(*p < 0.05, **p < 0.01, ***p < 0.001; Mann-Whitney
t test; graphs represent the mean + SEM of two
independent experiments; n = 9–12).
See also Movies S1 and S2.
Immunity
Bone Marrow CD8+ T Cell PrimingFinally, we examined the proliferative CD8+ T cell response
in Ccr1/ mice by BrdU incorporation on day 4 after MVA
i.d. injection. In the dLN the response was similar in WT and
Ccr1/ mice (Figure 3F). In contrast, the BM-associated MVA-
specific CD8+ T cell proliferation was lost in Ccr1/ mice
(Figure 3G).920 Immunity 37, 917–929, November 16, 2012 ª2012 Elsevier Inc.Together these results show that
CCR1 is necessary for neutrophils to
transport MVA from the dermis to the
BM after virus injection intradermally. In
the absence of this chemokine receptor,
neutrophil transport of MVA to the blood
and BM is reduced, and the subsequent
BM CD8+ T cell response is lost.
Depletion of BM Myeloid APCs
Abrogates MVA-Specific CD8+ T
Cell Priming in the BM
Myeloid lineage cells are the main APCs
present in the BM. In BALB/c mice, theydisplay a CD11b+F4/80+CD11cintI-Ad+ phenotype. We hypothe-
sized that the phagocytic cell compartment might be involved
in the cross-presentation of MVA-specific antigens. Therefore,
we examined the expression of activation markers on the
CD11b+F4/80+I-Ad+ BM and LN populations 2 days after i.d.
injection of PBS or MVA. After i.d. injection of MVA, BM
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Figure 3. Ccr1–/– Mice Have Reduced Neutrophil Transport of MVA
and No BM-Primed CD8+ T Cell Response
(A) Representative fields of ear skin 4 hr after i.d. injection of either PBS or
5 3 106 pfu MVA-EGFP in WT or Ccr1/ mice as indicated. Red-stained
neutrophils (Ly6G+) were found in the dermis surrounding the MVA-EGFP
(green fluorescence) localized in the dermis (scale bars represent 20 mm).
(B–E) Percentage of MVA-EGFP+ neutrophils 2 hr after i.d. injection of PBS or
107 pfuMVA-EGFP inWT orCcr1/mice. Results are represented for skin (B),
blood (C), dLN (D), and BM (E).
(F andG) Total number of BrdU+ dividing CD8+ T cells in the dLN (F) and BM (G)
of either WT or Ccr1/mice on day 4 after i.d. injection of 53 106 pfu MVA or
PBS (**p < 0.01, ***p < 0.001; Mann-Whitney t test; graphs represent the
mean + SEM of two separate pooled experiments, n = 6–12).
See also Figure S2.
Immunity
Bone Marrow CD8+ T Cell PrimingCD11b+F4/80+ cells exhibited an increased expression of MHC
class I and CD80 compared to control PBS mice (Figure 4B).
LN CD11b+F4/80+I-Ad+ cells of MVA-injected mice also showed
an increased expression of CD80 activation marker compared to
the same population in PBS-injected mice (Figure 4A). To further
demonstrate their antigen-presenting capacity, we performed an
ex vivo antigen presentation assay. In the absence of a tg or
clone-specific system, we purified CD8+ T cells from the dLN
of day 7 MVA-immunized mice and labeled them with CFSE.
These cells were then cultured with increasing numbers of flow
cytometry-sorted CD11b+F4/80+I-Ad+ cells from dLN and BM
of MVA-immunized mice (Figures 4C and 4D). In vitro cultureIwith CD11b+F4/80+I-Ad+ cells resulted in a significant T cell
proliferation as measured by reduced CFSE fluorescent intensi-
ties (Figures 4C and 4D).
To further demonstrate the role of CD11b+F4/80+ cells in the
BM T cell response, we used liposomes containing clodronate,
which have previously been shown to specifically deplete
phagocytic cells in vivo (Van Rooijen and Sanders, 1994). Mice
were treated with an i.v. injection of 200 ml liposomes containing
either clodronate or PBS at days 4 and 2 and the numbers of
CD11b+F4/80+ and CD11b+F4/80 cells were monitored. Intra-
venous treatment with clodronate had no effect on LN cells
(Figure 4E). In contrast it caused a significant depletion of
CD11b+F4/80+ cells in the BM (Figure 4F, p = 0.0086). We next
analyzed the effect of clodronate treatment on CD8+ T cell prolif-
eration at day 4 after MVA i.d. injection. Clodronate treatment did
not affect CD8+ T cell proliferation in the dLN (Figure 4G). In
contrast in the BM of clodronate-treated mice, no CD8+ T cell-
proliferative response to MVA was observed (Figure 4H).
We injected neutrophils (after in vitro culture with MVA) intra-
dermally into clodronate i.v.-treated mice (absence of phago-
cytic cells in the BM). We did not detect BM CD8+ T cell pro-
liferation in clodronate-treated mice despite the injection of
MVA-bearing neutrophils (Figure 4J). As expected, we observed
a proliferative CD8+ T cell response in the dLN after an injection
of MVA-bearing neutrophils (Figure 4I). Together, these data
suggest that the BM CD11b+F4/80+I-Ad+ myeloid APC popula-
tion depleted during i.v. clodronate treatment was necessary
for CD8+ T cell priming in the BM.
BM-Primed CD8+ T Cells Display a Differential Quality to
dLN-Primed T Cells
To determine whether this alternative source of antigen-specific
CD8+ T cells displays a similar functional outcome to dLN-
primed T cells, we characterized the T cell phenotype and cyto-
kine response. Therefore, we compared the expression of cyto-
kine receptors implicated in proliferation (IL-7R/IL-15R/IL-2R)
and activation markers (CD44/Ly6C/KLRG1) on antigen-primed
T cells in dLN and BM (Figure 5A). At day 5 postimmunization,
BM BrdU+CD8+ T cells exhibited higher expression of IL-7R,
IL-15R, IL-2R, and CD44 compared to LN BrdU+ T cells.
To assess the multifunctionality of CD8+ T cells that initiate
their proliferation in the BM (between days 4 and 7 after immuni-
zation), we performed intracellular staining for IFN-g, IL-2, and
TNF-a after an overnight culture with MVA. Boolean gating anal-
ysis was performed and the percentage of different cytokine-
producing subpopulations (Figures 5B and 5D) and their relative
percentages were examined (Figures 5C and 5E). On day 4, the
largest dLN detected CD8+ T cell responses were IL-2+ and
IFN-g+ single-positive cells, with smaller but significant popula-
tions of IFN-g+TNF-a+IL-2+, IFN-g+IL-2+, and TNF-a+ cells also
observed (Figures 5B and 5C). In contrast, in the BM the vast
majority (82%) of the detected CD8+ T cell response was
IFN-g+ single-positive cells (Figures 5B and 5C). Cytokine-
producing CD8+ effector T cells in the blood were not observed
on day 4, but by day 7, IFN-g+-secreting CD8+ T cells were
detected in the circulation (data not shown). On day 7 the dLN
CD8+ T cell response was much reduced compared with day
4, in contrast to the BM, which had significantly high percent-
ages of IFN-g+-, IFN-g+TNF-a+-, TNF-a+-, and IL-2+-producingmmunity 37, 917–929, November 16, 2012 ª2012 Elsevier Inc. 921
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Figure 4. Depletion of BM CD11b+F4/80+
Cells Leads to Loss of BMCD8+ T Cell Prolif-
erative Response
(A and B) H-2Kd (MHC-I) and CD80 expression
levels of dLN (A) and BM (B) CD11b+F4/80+I-Ad+
cells on day 2 after i.d. injection of MVA (dark line)
or PBS (gray line) as measured by flow cytometry
(isotype control staining: light gray).
(C and D) The percentage of CFSElo dividing
CD8+ T cells after 5 days in vitro culture with
CD11b+F4/80+I-Ad+ cells from dLN (C) and BM (D)
purified at day 2 after MVA i.d. immunization. Ratio
of CD11b+F4/80+I-Ad+ to CFSE+CD8+ T cells are
indicated.
(E and F) Total numbers of dLN (E) and BM (F)
CD11b+F4/80+ and CD11b+F4/80 cells after i.v.
injections of liposomes (days 4 and 2) loaded
with clodronate (clod.) or PBS (***p < 0.001; Mann-
Whitney t test; data represent the mean + SEM of
one of three separate experiments, n = 6).
(G and H) Total number of dLN (G) and BM (H)
BrdU+CD8+ T cells on day 4 after i.d. injection of
53 106 pfu MVA or PBS and in the presence of i.v.
injections of liposomes (days 4 and 2) loaded
with clodronate or PBS (*p < 0.05, ***p < 0.001;
Mann-Whitney t test, graphs represent the mean +
SEM of three independent experiments, n = 9–12).
(I and J) Total number of dLN (I) and BM (J) BrdU+
CD8+ T cells on day 4 after i.d. injection of 5 3 106
neutrophils (± in vitro culture with MVA) and in the
presence of i.v. injections of liposomes (days 4
and 2) loaded with clodronate or PBS (*p < 0.05 ;
Mann-Whitney t test; graphs represent the mean +
SEM, n = 6).
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Figure 5. BM CD8+ T Cells Have Different Phenotype and Cytokine Potential Compared to dLN CD8+ T Cells
(A) The expression levels of dLN (gray) and BM (black) BrdU+ dividing CD8+ and CD4+ T cells for IL-7R, IL-15R, IL-2R, CD44, Ly6C, and KLRG1 on day 4 after i.d.
injection of 5 3 106 pfu MVA.
(B–E) The percentages (B, D) and relative proportions (C, E) of MVA-specific IFN-g/IL-2/TNF-a-producing CD8+CD3+ T cells from dLN and BM, after overnight
in vitro restimulationwithMVA on days 4 (B, C) and 7 (D, E) after i.d. injection of 53 106 pfuMVA (graphs represent themean of one of three repeated experiments,
n = 5; values on pie charts indicate the percentage of total detected cytokine-producing cells, less than 1% not indicated).
(F) The proportions ofMVA-specific IFN-g/GranzymeB-producingCD8+CD3+ T cells fromdLN andBMafter overnight in vitro restimulationwithMVA (0.1 pfu/cell)
on day 7 after i.d. injection of 5 3 106 pfu MVA.
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Figure 6. P24-Specific CD8+ T Cells Primed in dLN and BM after Intradermal Immunization Have a Distinct Gene Expression Profile
(A) Using H2-Kd-P24 peptide (AMQMLKETI) pentamer+ and CD8+CD3+ staining, P24-specific CD8 T cells were sorted by flow cytometry from dLNs and BM
5 days after i.d. injection of 53 106 MVA-gag. RNA from three cell-sorting experiments of five were pooled to give five experimental replicates for either dLN- or
BM-primed P24-specific CD8+ T cells and naive CD8+ T cells (CD62LhiCD44medCD8+CD3+ T cells sorted from LNs of noninjected mice). Hierarchical clustered
heat map of P24 CD8+ T cells sorted from dLNs and BM based on the gene expression of five distinct clusters.
(B) Network diagram of genes depicted in cluster 1 corresponding to cell death pathway (intensity of red molecule color indicates the degree of upregulation in
dLN-primed CD8+ T cells compared to BM-primed CD8+ T cells, Ingenuity Pathway Analysis).
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Bone Marrow CD8+ T Cell Primingcells (Figure 5D). However, cytokine producing profiles between
dLN and BM cells were similar at this point, perhaps reflecting
a mixed population of circulating MVA-specific CD8+ effector
T cells, with a dominance of IFN-g+ cells (Figure 5E).
No Granzyme B production was detected on day 4 after MVA
injection, but on day 7 populations of Granzyme B+ and Gran-
zyme B+IFN-g+ T cells were detected in the LN (Figure 5F).
However, only a minor population (11% of responders) of Gran-
zyme B+ T cells was observed in the BM (Figure 5F) in contrast to
major Granzyme B+ T cells detected in the dLN. This suggested
that BM-primed CD8+ T cells had less cytotoxic capacity than
dLN-primed T cells. Together these results demonstrate that
BM-primed CD8+ T cells have a different phenotype and cyto-
kine profile compared to T cells primed in the dLN.
To examine differences resulting from priming in the different
organs of dLN and BM, we performed genome-wide microarray
analysis. To ensure that gene expression was analyzed on the
same antigen-specific cells, mice were immunized with MVA-
gag and P24-specific CD8+ T cells were sorted from the dLN
and BM of day 5 immunized mice. Naive CD8+ T cells (based
on expression of CD62L and CD44) were also sorted from
nonimmunized mice and RNA extracted. RNA was pooled from
three independent cell-sorting experiments of five mice per
group. Therefore, five experimental replicates were prepared
for each of the three groups (dLN, BM, and naive CD8; Figure 6A)
for a total of 15 samples. To identify genes that would discrimi-
nate between the three different groups, a one-way ANOVA
(p % 0.01) with subsequent K-median clustering analysis was
performed. We then performed a discriminatory gene analysis
between virus-specific CD8+ T cells isolated from dLN and
BM. This last step highlights the differences of virus-specific
CD8+ T cells between the two organs. One-way ANOVA
returned a perfect separation of the sample groups by hierar-
chical clustering based on the expression of 251 genes (Fig-
ure 6A and Tables S1 and S2). The differential genes were
grouped into five clusters and analyzed with Ingenuity Pathway
analysis. Intriguingly, cluster 1, which had significantly lower ex-
pression in BM CD8+ T cells, contained genes associated with
cell death and inflammation (Figures 6A and 6B; Table S1). These
results suggest that the BM environment promotes increased
cell survival, indicative of preferential differentiation into a
memory cell population. This is also what we observed in a longi-
tudinal analysis of the effector MVA-specific IFN-g response by
ELISPOT in the BM compared to the dLN (Figure 6C). The early
kinetics of response mirrored the proliferation data, with a signif-
icant IFN-g response observed on day 3 in the LN and BMon day
4 (Figure 6C). However, it remained significantly elevated as far
as day 112 only in the BM (Figure 6C), supporting the hypothesis
of memory T cell generation in this organ. Flow cytometry
analysis of the cytokine response profile revealed an effector/
memory phenotype of BMCD8+ T cells (Figure 6D). These results
of transcriptional and functional analyses suggest a short or
absent contraction phase in the BM compared to the LN, which(C) MVA-specific IFN-g ELISPOT results from BM and dLN on days 0, 3, 4, 7, 14,
Whitney t test compared against Day 0 control; graph represents the mean + SE
(D) The percentages of MVA-specific IFN-g/IL-2/TNF-a-producing CD8+CD3+ T
restimulation with MVA (0.1 pfu/cell) on day 112 after i.d. injection of 5 3 106 pfu
See also Tables S1 and S2.
Imay favor the direct differentiation of BM-primed effector CD8+
T cells into memory virus-specific CD8+ T cells.
In addition, several other clusters of genes were significantly
differentially expressed between BM and dLN virus-specific
CD8+ T cells. Cluster 2 contained genes involved in lipid and
amino acid metabolism and also had significantly lower gene
expression in BM T cells compared to LN-primed T cells (Fig-
ure 6A; Table S1). A small group of genes in cluster 3 were diffi-
cult to attribute to a particular canonical pathway, although one
genewas identified as involved in cell morphology. The other two
clusters that were identified to separate dLN and BM CD8+
T cells showed a higher expression in BM-primed cells. Cluster
4 was identified as immune cell trafficking and RNA posttransla-
tional modification associated genes (Table S2), and cluster 5
included cell growth and proliferation and cell signaling genes
(Table S2). The local microenvironment and stromal cells are
increasingly recognized to play a role in shaping the primed
T cell response (Tokoyoda et al., 2010). The differences
observed here between BM- and dLN-primed T cells may also
reflect interactions with local stroma and microenvironment.
Together these data demonstrate that after immunization by
i.d. route, priming in the BM induces a qualitatively different
CD8+ T cell population compared to priming in the dLN and
may represent an alternative source of CD8+ effector T cells
with a preferential differentiation into memory CD8+ T cells.
DISCUSSION
We report here a previously unrecognized consequence of neu-
trophil recruitment to a site of i.d. injection on BM T cell priming.
We defined an alternative source of BM-primed antigen-specific
CD8+ T cells that displayed a qualitatively different cytokine-
producing phenotype to dLN-primed antigen-specific CD8+
T cells. Gene expression analysis provided further evidence
that these populations were qualitatively distinct from each
other. We also demonstrated that neutrophils migrated in a
CCR1-dependant manner from the dermal site of antigen immu-
nization and subsequently transported the antigen into the BM.
However, we showed that myeloid-resident antigen-presenting
cells were required for priming of the virus-specific CD8+ T cell
response in the BM.
Tripp et al. (1997) identified the BM as a site of T cell priming,
although only under conditions of disrupted lymphocyte traf-
ficking. Splenectomized mice treated with lymphocyte migration
blocking antibodies were immunized intranasally with an influ-
enza virus, which resulted in a BM T cell response (Tripp et al.,
1997). In separate studies, LCMV was detected in BM 3 days
after an intraperitoneal infection (Slifka et al., 1995), though a
virus-specific response was not found until day 8 (Slifka et al.,
1997). This group examined only CD8+ T cell responses dis-
playing cytotoxic function, perhaps missing an earlier T cell
response. More recently it has been demonstrated that the BM
can function as a site of tg T cell priming, under conditions ofand 112 after i.d. injection of 5 3 106 pfu MVA (*p < 0.05, ***p < 0.001; Mann-
M of three separate pooled experiments, n = 9–12).
cells from dLN (spotted boxes) and BM (white boxes), after overnight in vitro
MVA.
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was performed with adoptive transfer of high number of tg
T cells by i.v. route, thereby limiting the interpretation of the
results.
In numerous previous studies, the BM has been identified as
a preferential site of homeostatic proliferation for memory
CD8+ T cells (Becker et al., 2005; Parretta et al., 2005, 2008).
Because it is recognized to provide an optimum environment
for dividing T cells andmemorymaintenance, our results suggest
that i.d. delivery of antigen induced early primed CD8+ T cells
that may benefit from this distinct environment. Proliferating
BM antigen-specific CD8+ T cells had higher levels of IL-7R
and CD44 expression compared to LN T cells, indicating that
priming in the BM may promote early memory T cell develop-
ment. Because high expression of CD44 is required for access
to BM survival niches, its expression may serve as a regulator
of competing T cells (Di Rosa and Santoni, 2003).
Furthermore, gene expression data revealed that priming of
T cells in the BM resulted in a qualitatively different response
to priming in the LN. Our approach identified 251 genes that
had highly significant differential expression levels between cells
from the two organs. Intriguingly, the gene cluster that showed
the lowest expression in BM cells compared to LN-primed and
naive cells is implicated in cell death, suggesting that the
BM environment enhances cell survival and proliferation. This
systems biology approach suggests that the unique environment
of the BM allows for priming of a T cell in a highly proliferative
but metabolically restrained manner. However, this microarray
gene analysis requires further exploration by more quantitative
approaches such as quantitative PCR or RNA sequencing that
will be performed in the future. It does, however, reinforce the
qualitative difference observed in BM-primed antigen-specific
CD8+ T cells compared to the LN-primed antigen-specific CD8+
T cells.
Although we observed proliferating CD4+ T cells on day 4 in
the BM, blockingmigration experiments revealed that these cells
were primed in the dLN. Tokoyoda et al. (2009) also recently re-
ported the early arrival of memory precursor CD4+ T cells in the
BM after immunization. Whether these CD4+ T cells provide help
to the proliferating CD8+ T cells at the same time as receiving
memory survival signals will require further investigation.
We have previously reported the recruitment of neutrophils
after MVA i.d. injection and its subsequent transport to the dLN
(Abadie et al., 2009). Indeed, after i.d. injection, neutrophils rep-
resented only 7% of the cellular compartment that transports the
MVA to the dLN, whereas monocyte/macrophage and DCs rep-
resented more than 85% of MVA+ cells. It has been previously
shown that after local infection, vaccinia virus infects macro-
phages and DCs in the dLN and only DCs present antigen to
naive CD8+ T cells (Norbury et al., 2002). Neutrophils were the
only cells that we have identified transporting MVA to the BM
(as shown in Figure S3). In addition, it has also been reported
that senescent neutrophils home to the BM where they are en-
gulfed by resident macrophages (Furze and Rankin, 2008b).
Therefore, we speculated that it was this migration pathway
that transported the antigen to the BM. The presence of virus
carrying neutrophils in the BM, which expressed CXCR4
in vitro, confirmed this hypothesis. It has been shown that
CXCR4 acts as a chemokine receptor for the return to BM after926 Immunity 37, 917–929, November 16, 2012 ª2012 Elsevier Inc.senescence (Martin et al., 2003) whereas CCR7 is involved in
the migration of neutrophils to LNs (Beauvillain et al., 2011).
Although they were low in number, they were consistently seen
to enter the sinusoidal compartments of the BM as previously
described (Furze and Rankin, 2008b). Interestingly, neutrophils
have been previously identified to carry latex beads to the
BM after an i.v. injection (Tacke et al., 2006). Neutrophils arrived
in the BM within 4 hr, which is consistent with our results.
They were observed to be undergoing apoptosis and by day 2
the majority of the beads in the BM were found in monocytes
rather than neutrophils. It has been previously demonstrated
that antigen-loaded DCs could migrate to the BM (Cavanagh
et al., 2005). However, their migration time of between 24 and
48 hr was slower than the rapid migration we observed for
neutrophils. Once in the BM, the DCs could trigger central
memory T cell responses (Cavanagh et al., 2005), in contrast to
the early T cell priming that we observed after neutrophil antigen
transport.
Whether this neutrophil migration to the BM also occurs after
bacteria or particle uptake as previously reported for the dLN
(Abadie et al., 2005; Maletto et al., 2006) remains to be investi-
gated. The presence of donor neutrophils in the BM of NSG
mice showed that neutrophils did not require passage through
the dLN to access the blood. This concept of reverse transmigra-
tion has been reported for neutrophils in zebrafish (Mathias et al.,
2006) and in mice (Woodfin et al., 2011). However, whether this
phenomenon is really occurring in our model or is a result of local
tissue damage and inflammation caused by the i.d. injection
requires further investigation to clarify. Nevertheless, it is impor-
tant to know whether this type of migration also occurs after
more severe viral infections, because invading viruses or bac-
teria can use neutrophils to spread throughout the body. This
‘‘Trojan horse’’ theory has been reported for Leishmania and
other intracellular microbes, which take advantage of neutrophil
engulfment by macrophages to infect these cells (Laskay et al.,
2003). However, because MVA is a highly attenuated viral
strain, it may induce different intracellular signals compared to
microbes such as Leishmania that appear to have evolved strat-
egies to survive within neutrophils (Jochim and Teixeira, 2009).
Infection with MVA has been shown to induce the expression
of CCL2, CCL3, CCL4, and CXCL10 by monocytes (Lehmann
et al., 2009). These chemokines can serve as chemoattractants
for neutrophils to migrate within tissues. However, of signifi-
cance reduced MVA-EGFP+ neutrophils were observed in the
blood and BM of Ccr1/ mice, suggesting that this receptor
was important for their migration from infected tissue. We also
showed that CCR1 is not required for neutrophil entry in the
BM. Intriguingly Ccr1/ mice were previously shown to be
more resistant to Leishmania infection (Rodriguez-Sosa et al.,
2003), but the authors did not examine the specific role of neutro-
phils in this study.
The loss of the BM CD8+ T cell response in clodronate-treated
mice revealed that BM phagocytic cells were responsible for
priming the CD8+ T cell response. Furthermore, flow cytometry
phenotyping of the clodronate-sensitive CD11b+F4/80+I-Ad+
BM cells on day 2 after MVA injection revealed an increase in
MHC class I and CD80 expression. These activation markers
were also upregulated on the CD11b+F4/80+I-Ad+ dLN popula-
tion. Furthermore, a previous study, which demonstrated the
Immunity
Bone Marrow CD8+ T Cell PrimingBM as a potential site of T cell priming (Feuerer et al., 2003),
showed that both F4/80+ and CD11c+ cells were capable of
priming a tg T cell response.
The results provided here demonstrate a consequence of
neutrophil virus capture in the dermis at the site of antigen
delivery. The transport of virus by neutrophils to the BM has
implications for numerous pathologies as well as opening up
therapeutic potential for targeting this unique environment and
exploiting this alternative source of primed CD8+ T cells.
EXPERIMENTAL PROCEDURES
Mice and Injections
Female BALB/c, C57BL/6, and nonobese diabetic-SCID interleukin-2 gamma
chain receptor null mice (NSG) were obtained from Charles River Laboratories
(L’Arbresle, France) and Ccr1/ mice (6–8 weeks old) on both BALB/c and
C57BL/6 background were used (Gao et al., 1997). All animals were housed
under specific-pathogen free conditions (Centre d’Experimentation Fonction-
nelle, Paris, France). All experiments complied with local animal experimenta-
tion and ethics committee guidelines.
Intradermal injections were performed in the ear pinna as previously
described (Abadie et al., 2009). For depletion of BM phagocytic cells, mice
were injected intravenously with a standard suspension (200 ml) of clodro-
nate-loaded liposomes 4 and 2 days before virus injection. Clodronate was
a gift from Roche Diagnostics (Van Rooijen and Sanders, 1994). For lympho-
cyte migration blocking experiments, mice were injected intraperitoneally
with 25 mg FTY-720 every 24 hr (Sigma, France). For in vivo depletion of neutro-
phils, mice were injected intraperitoneally with 0.5 mg 1A8 mAb (BioXCell)
24 hr prior to immunization and every subsequent 48 hr thereafter.
Virus
Wild-type modified vaccinia Ankara (MVA) and the recombinant strain of
MVA expressing the enhanced Aequoriae green fluorescent protein (EGFP
MVATG15938) and HIV gag protein were originally provided by Transgene
Laboratories (Strasbourg, France). The EGFP protein was fused to p11K75
(a generous gift from R. Wittek, Lausanne), which is a strong early promoter.
Therefore, fluorescent-positive cells are infected with the virus. Mice were
immunized intradermally in the ear pinna with either 53 106 or 107 pfu of virus.
Tissue Preparations
Before tissue removal, mice were bled by retro orbital vein puncture. To
discriminate between cells resident in BM and those in the blood of BM,
mice were perfused with PBS by intracardiac injection to the right ventricle.
Femur and tibias were removed, cleared of muscle and connective tissue,
and flushed with PBS-10%FCS to recover BM cells. Blood was centrifuged
on a histopaque density gradient for extraction of lymphocytes. Draining lymph
nodes were removed and single-cell suspensions prepared and cells were
counted by trypan blue exclusion. Flow cytometry staining of ear cells and
histology examination were performed as previously described (Liard et al.,
2012; Mahe et al., 2009).
BrdU Labeling and Detection
For detection of T cell proliferation with BrdU, mice were injected twice intra-
peritoneally 12 hr apart with 100 ml BrdU-PBS (0.8 mg/ml). The following day
mice were perfused and blood, BM, and draining LNs were removed and
stained for BrdU (APC BrdU flow kit BD) and for CD3, CD8, and CD4 markers.
For calculation of the total number of BM cells, the cell count of one femur and
tibia was estimated to represent 6% and 3%, respectively, of the total BM and
cell recovery estimated at 50% as previously described (Benner et al., 1974;
Hunt, 1987). Our cell counts were in agreement with those reported in the liter-
ature (Benner et al., 1974; Hunt, 1987; Parretta et al., 2008).
Adoptive Transfer
For adoptive transfer experiments, neutrophils were purified from the BM of
donor mice by purification with Ly6G-PE and PE-beads (Miltyeni) and cultured
for 1 hr with MVA-EGFP or MVA-WT (1 pfu/cell). Subsequently, they were in-Ijected i.d. in ear or i.v. as indicated. For Hoescht and CFSE labeling, neutro-
phils were incubated with Hoescht (1 mmol/l) or CFSE (2.5 mmol/l) for 10 min
at 37C prior to injection.
Flow Cytometry and ELISPOT Assays
Cells were acquired on a FACS Calibur, FACS Canto, or LSR II (BD) and
analyzed with FlowJo software (Treestar Inc, San Carlos, CA). Cells were
stained with Ly6G (1A8), Ly6C (AL-21), CD11b (M1/70), CD11c (HL3), CD40
(HM40-3), I-Ad (AMS.32.1), H2-Kd (SF1-1.1), CD86 (GL1), CXCR4, Annexin
V (all BD), and F4/80 (Serotec).
For intracellular cytokine staining, cells were cultured overnight with MVA
(0.1 pfu/cell), with BrefeldinA (5 mg/ml) added for the final 4 hr. CD3 (145-
2C11), CD8 (53-6.7) (eBioscience, France), and CD4 (RM4-5, BD) antibodies
were used for membrane staining, and intracellular cytokine (IFN-g, IL-2,
and TNF-a or Granzyme B) staining was performed and analyzed with FlowJo
software as previously described (Abadie et al., 2009).
The IFN-g ELISPOT kit (Diaclone, Strasbourg, France) was used accord-
ing to manufacturer’s instructions and as previously described (Abadie
et al., 2009). The resulting spots were counted on the ELISPOTReader System
(AID).
Gene Expression Arrays
Pentamer H2Kd-AMQMLKETI (HIV-gag P24 peptide, ProImmune) CD8+CD3+
T cells were sorted by flow cytometry (FACS Aria II, BD) from dLNs and BM
5 days after i.d. injection of 5 3 106 MVA-gag. CD62LhiCD44intCD8+CD3+
T cells were also sorted from LN of naive mice as naive CD8+ T cell population.
Cells were sorted in three independent experiments of five mice each and the
RNA was pooled from the three experiments to give five experimental repli-
cates in each group. RNA was amplified with the miltenyi SuperAmp protocol
and the resulting cDNAswere analyzed on 8x10KWholeMouse GenomeOligo
Microarrays (Agilent single color). For data analysis reporters were filtered and
only those showing significance (p % 0.05) in four out of five replicates, with
a median normalized log2 intensity R6 in at least one group, assignment to
a valid Entrez Gene Identity (and no assignment to a lincRNA) were selected.
This resulted in 16,239 reporters from an initial 55,681. To identify genes that
would discriminate between the two different groups a one-way ANOVA
(p % 0.01) with subsequent K-median clustering analysis was performed
with MedV 4.7.4 software that identified 251 genes spread in 5 clusters. Inge-
nuity Pathway Analysis (IPA) (Ingenuity Systems Inc.) software was used to
identify metabolic and signaling pathways.
Statistical Analysis
Data are presented as themean plus the standard error of themean. Statistical
analyses compared the groups of mice with a Mann-Whitney t test (Prism soft-
ware). p values of less than 0.05 were considered statistically significant.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE4173.
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